McDermott Will & Schulte has advised Sagard NewGen. Sagard NewGen has completed a minority investment in Quipment, a prominent provider of equipment solutions for clinical trials,...
Sagard NewGen Announces Minority Investment in Quipment
MaaT Pharma Licenses European Rights to Xervyte for aGvHD to Clinigen
McDermott Will & Emery has advised MaaT Pharma. MaaT Pharma has entered into an exclusive long-term license and distribution agreement with Clinigen for its therapy Xervyte...


























